Max Robotics — Global Service Robot Directory + US Certification

About

Dr. Hirotake Kodama is a urologic oncologist whose research focuses on optimizing surgical outcomes for patients with prostate and bladder cancers, with a particular emphasis on the interplay between patient frailty, comorbidity, and treatment selection. His most cited work, the FRART-PC Study (2020, 19 citations), established a critical framework for understanding how frailty and comorbidity influence surgical contraindication in localized prostate cancer, directly challenging conventional treatment paradigms. More recently, Dr. Kodama has advanced the field of robotic surgery through a landmark multicenter retrospective study (2025) comparing robot-assisted radical cystectomy (RARC) to open radical cystectomy (ORC) in muscle-invasive bladder cancer. This work provides real-world evidence on the impact of surgical approach on peritoneal carcinomatosis and prognosis—a previously underexplored area with significant clinical implications. By integrating frailty assessment into oncologic decision-making and rigorously evaluating robotic surgical techniques, Dr. Kodama’s research bridges the gap between surgical innovation and personalized patient care, offering actionable insights for urologists navigating complex treatment decisions in high-risk populations.